News

A mouse model has helped scientists uncover the biological mechanisms behind the autoimmune condition dermatomyositis.

In a new study, researchers have found that a protein called FOXO1 improves the survival and function of CAR T cells, which may lead to more effective CAR T cell therapies and could potentially expand its use in difficult-to-treat cancers.

The molecular mechanisms behind the action of the hepatitis B and D virus inhibitor bulevirtide have been revealed, potentially paving the way to more targeted treatments.

Language models can be used to home in on partial genome sequences and optimize those sequences to study biology and improve medicine, and have designed more effective mRNA vaccines.

New Phase 1 data from Memorial Sloan Kettering Cancer Center shows an investigational cancer vaccine may elicit lasting immune response in patients with pancreatic cancer.

An oral vaccine against recurrent UTIs could reduce the need for antibiotic treatment.

Fecal microbiota transplantation improves motor symptoms in Parkinson’s disease patients after 12 months. That's according to data from the GUT-PARFECT trial that recruited 46 Parkinson's disease patient.

A study has found older adults’ weaker immune response can be attributed to their relative deficiency in a specific type of T cell. This deficiency has been shown to account for poorer vaccination responses in the older population.

Mayo Clinic scientists have developed an immunotherapy strategy that utilizes CAR-MSCs. The approach shows potential in targeting inflammatory disease sites more precisely and improving immunosuppression and healing outcomes.

Engineering a virus that infects a frog-killing fungus could be the answer to controlling the spread of disease and saving the amphibians.